International Journal of Clinical Research

Objective To investigate the application value of Apatinib combined with chemoradiotherapy in the treatment of adult brain stem glioma. Methods From January 2022 to January 2023, 48 adult patients with brain stem glioma in our hospital were selected and grouped into control group and study group by computer random drawing method, with 24 cases in each group. The control group received radiotherapy and chemotherapy, while the study group received apatinib treatment. The effect of Apatinib combined with radiotherapy and chemotherapy was comprehensively evaluated from three aspects: short-term efficacy, changes in immune function before and after treatment, life conditions after treatment and mental state. Results The objective response rate of the two groups was higher in the study group (65.50%) than in the control group (45.83%), and the difference was significant by χ2 test (P < 0.05). Before treatment, there was no significant difference in immune indexes between the two groups (P > 0.05). After treatment, CD3+, CD4+, CD4+/CD8+ in the control group were lower than those in the study group (P < 0.05). The KPS and MMSE scores of the two groups were compared, and the difference between the two groups was significant (P < 0.05), and the study group was higher than the control group. Conclusion Apatinib combined with chemoradiotherapy is effective in the treatment of adult brain stem glioma, which is of great value in improving the quality of life and mental state of patients.

Apatinib; Chemoradiotherapy; Adult brain stem glioma